A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
What is the purpose of this trial?
This study will assess the safety and efficacy of VS-6766 monotherapy and in combination with Defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
- GenderFemale only
- Trial withVerastem, Inc.
- Start Date10/21/2021
- End Date06/30/2023
- Last Updated10/25/2021
- Study HIC#2000030079